CO5640091A2 - Antagonista de un receptor sensible al calcio - Google Patents

Antagonista de un receptor sensible al calcio

Info

Publication number
CO5640091A2
CO5640091A2 CO05106148A CO05106148A CO5640091A2 CO 5640091 A2 CO5640091 A2 CO 5640091A2 CO 05106148 A CO05106148 A CO 05106148A CO 05106148 A CO05106148 A CO 05106148A CO 5640091 A2 CO5640091 A2 CO 5640091A2
Authority
CO
Colombia
Prior art keywords
group
alkyl
atom
integer
alkoxy
Prior art date
Application number
CO05106148A
Other languages
English (en)
Inventor
Yuko Shinagawa
Teruhiko Inoue
Toshihiro Kiguchi
Taku Ikenogami
Naoki Ogawa
Kenji Fukuda
Takashi Nakagawa
Masanori Shindo
Yuki Soejima
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CO5640091A2 publication Critical patent/CO5640091A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)

Abstract

1.-Un compuesto representado por la fórmula siguiente (1): en donde n es 0 ó 1, p es un entero de 1 a 3, R1 es un grupo hidroxilo, un grupo alcoxi de C1-6 o RA, en donde RA es RC- OC(=O)C1-4 alquileno-O- u OH-NH-, en donde RC es un grupo alquilo de C1-6 o un grupo cicloalquilo de C3-6, R2 y R3 son iguales o diferentes y cada uno es un átomo de hidrógeno, un grupo hidroxilo, un átomo de halógeno, un grupo amino, grupo acilamino de C1-7, un grupo haloalquilo de C1-6, un grupo carboxilo, un grupo alcoxicarbonilo de C1-6, un grupo alcoxi de C1-6, un grupo haloalcoxi de C1-6, un grupo alquilo de C1-6, un grupo hidroxialquilo de C1-6, un grupo acilamino C1-7-alquilo C1-6, un grupo alquenilo de C2-6, un grupo aralquilo, un grupo fenilo, grupo alquilamino de C1-6, un grupo di(alquilo C1-6)amino, un grupo alcoxi C1-6-alquilo C1-6, un grupo mercapto, un grupo ciano, un grupo nitro, un grupo morfolino, un grupo piperidino o un grupo pirrolidino, o R2 y R3 se unen para formar un grupo etilenoxi, X1 es -C=C-, -C=N-, un átomo de oxígeno ó átomo de azufre, Z es -S-, -SO-, -SO2-, -(CH2)m1-O-, -O-(CH2)m1-, -(CH2)m2-NH-, -NH(CH2)m2, -(CH2)m3--N(CH3)-, -N(CH3)-(CH2)m3-, un grupo alquileno de C1-4, -SO2-N(CH3)-, -N(CH3)-SO2-, -NHCO-, -CONH- o un grupo alquileno de C2-4, en donde m1, m2 y m3 son cada uno un entero de 0 a 2, X2 es -C=C-, un átomo de oxígeno o un átomo de azufre, R4 es un grupo alquilo de C1-6 o un grupo cicloalquilo de C3-6, R5 es un átomo de hidrógeno o RB, en donde RB es un grupo acilo de C1-7 opcionalmente sustituido por un grupo carboxilo, Y es un átomo de carbono o un átomo de nitrógeno, y R6, R7 y R8 son iguales o diferentes y cada uno es un átomo de hidrógeno, un átomo de halógeno, un grupo de alquilo C1-6, un grupo alcoxi de C1-6, un grupo haloalquilo de C1-6, un grupo haloalcoxi de C1-6, un grupo carboxilo, un grupo hidroxilo, un grupo ciano, un grupo nitro, un grupo fenilo, un grupo cicloalquilo de C3-6, un grupo di(alquilo C1-6)aminocarbonilo o un grupo hidroxialquilo de C1-6, o R6 y R7 adyacentes se unen para formar -CH=CH-CH=CH-, -C(OH)=CH-CH=CH-, -CH=C(OH)-CH=CH-, -O-(CH2)k1-O-, -O-(CH2)k2- ó -(CH2)k3-, en donde k1 es un entero de 1 a 4, k2 es un entero de 2 a 5, k3 es un entero de 3 a 6, con la condición de que cuando R2 y R3 son átomos de hidrógeno y n es 1, entonces Z debe ser un grupo distinto de -SO2-N(CH3)- en donde el átomo de azufre se une al anillo V y un átomo de hidrógeno se une al anillo W, una sal farmacéuticamente aceptable del mismo o una forma ópticamente activa del mismo.
CO05106148A 2003-04-23 2005-10-19 Antagonista de un receptor sensible al calcio CO5640091A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003119131 2003-04-23

Publications (1)

Publication Number Publication Date
CO5640091A2 true CO5640091A2 (es) 2006-05-31

Family

ID=33308093

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05106148A CO5640091A2 (es) 2003-04-23 2005-10-19 Antagonista de un receptor sensible al calcio

Country Status (31)

Country Link
US (4) US7304174B2 (es)
EP (3) EP2308828A3 (es)
JP (1) JP3751312B2 (es)
KR (1) KR100696927B1 (es)
CN (2) CN101723921A (es)
AR (1) AR044075A1 (es)
AT (1) ATE452121T1 (es)
AU (1) AU2004232604C1 (es)
BR (1) BRPI0407097A (es)
CA (1) CA2513738C (es)
CL (1) CL2004000868A1 (es)
CO (1) CO5640091A2 (es)
CY (1) CY1109880T1 (es)
DE (1) DE602004024668D1 (es)
DK (1) DK1619180T3 (es)
ES (1) ES2337576T3 (es)
HK (1) HK1083096A1 (es)
HR (1) HRP20100042T1 (es)
IL (1) IL169575A (es)
MX (1) MXPA05007609A (es)
MY (1) MY138734A (es)
NO (1) NO20054868L (es)
NZ (1) NZ541188A (es)
PE (1) PE20050460A1 (es)
PL (1) PL1619180T3 (es)
PT (1) PT1619180E (es)
RU (1) RU2315036C2 (es)
SI (1) SI1619180T1 (es)
TW (1) TWI329628B (es)
WO (1) WO2004094362A1 (es)
ZA (1) ZA200505587B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
EP1630157A4 (en) * 2003-05-28 2007-05-23 Japan Tobacco Inc ANTAGONIST OF CASR
WO2005077886A1 (en) * 2004-02-06 2005-08-25 Smithkline Beecham Corporation Calcilytic compounds
EA200802166A1 (ru) * 2006-04-20 2009-06-30 Эмджен Инк. Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
CA2681582C (en) 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
US8039514B2 (en) * 2008-06-05 2011-10-18 Asahi Kasei Pharma Corporation Sulfonamide compounds and use thereof
CA2748250A1 (en) * 2008-12-24 2010-07-01 Daiichi Sankyo Company, Limited Indanyl compounds
WO2010074088A1 (ja) * 2008-12-24 2010-07-01 第一三共株式会社 環状アミン化合物
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
WO2010103429A1 (en) * 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
PE20120520A1 (es) * 2009-03-26 2012-05-14 Japan Tobacco Inc Proceso para producir compuesto de acido carboxilico
WO2010113860A1 (ja) * 2009-03-31 2010-10-07 第一三共株式会社 ビフェニル－環状アミン化合物
EP2435400A2 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2435404A1 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
CN103228619A (zh) 2010-11-26 2013-07-31 利奥制药有限公司 钙传感受体活性化合物
WO2012069421A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
WO2012069419A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
JP2014500882A (ja) * 2010-11-26 2014-01-16 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
GB201113538D0 (en) * 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
IN2015MN00421A (es) * 2012-08-27 2015-09-04 Lupin Ltd
EP3468550A4 (en) 2016-06-13 2020-02-12 Syneurx International (Taiwan) Corp. USE OF LITHIUM BENZOATE FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
US20230041996A1 (en) * 2019-12-09 2023-02-09 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Calcium-sensing receptor agonist compound and application thereof
BR112023002107A2 (pt) 2020-08-04 2023-03-07 Calcilytix Therapeutics Inc Formulações de compostos trifenil calcilíticos
KR20230112609A (ko) 2020-09-18 2023-07-27 캘시리틱스 테라퓨틱스, 인코포레이티드 상염색체 우성 저칼슘혈증 타입 1(adh1)의 치료를 위한 트리페닐 칼시라이틱 화합물

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE633760A (es) * 1963-06-18
DD207203A1 (de) * 1982-06-21 1984-02-22 Peter Meisel Verfahren zur herstellung von epoxypropylethern
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
US5276008A (en) * 1990-08-09 1994-01-04 Bayer Aktiengesellschaft Substituted 4,5-diamino-1,2,4-triazol-3-(thi)ones
US6818660B2 (en) 1996-04-09 2004-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
AU726659B2 (en) * 1996-04-09 2000-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
EP0827746B1 (en) * 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
AR014975A1 (es) 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento
US20020052509A1 (en) 1998-04-08 2002-05-02 Smithkline Beecham Corporation Calcilytic compounds and method of use
MY121054A (en) 1998-04-08 2005-12-30 Smithkline Beecham Corp Calcilytic compounds as calcium receptor antagonists.
US6334338B1 (en) * 1998-07-02 2002-01-01 Lucent Technologies Inc. Sol gel process of making a fiber preform with removal of oxide particles
EP1104411A4 (en) 1998-08-12 2002-10-24 Smithkline Beecham Corp CALCILYTIC COMPOUNDS
US6291459B1 (en) * 1998-08-12 2001-09-18 Smithkline Beecham Corporation Calcilytic compounds
CN1150195C (zh) * 1998-10-23 2004-05-19 霍夫曼-拉罗奇有限公司 双环氮杂环
PE20001456A1 (es) 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
AU7072200A (en) * 1999-08-27 2001-03-26 Procter & Gamble Company, The Fast-acting formulation components, compositions and laundry methods employing same
IL139073A0 (en) 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
MY159417A (en) 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
US20030018203A1 (en) * 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
US6867299B2 (en) * 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
WO2002007673A2 (en) 2000-07-21 2002-01-31 Smithkline Beecham Corporation Calcilytic compounds
KR100785675B1 (ko) * 2000-08-11 2007-12-14 니뽄 다바코 산교 가부시키가이샤 칼슘 수용체 길항약
BR0114884A (pt) 2000-10-25 2004-07-06 Smithkline Beecham Corp Compostos calcilìticos
AU2002230579A1 (en) 2000-10-25 2002-05-06 Smithkline Beecham Corp Calcilytic compounds
AR038658A1 (es) * 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
US6864267B2 (en) 2001-07-16 2005-03-08 Smithkline Beecham Corporation Calcilytic compounds
EP1630157A4 (en) * 2003-05-28 2007-05-23 Japan Tobacco Inc ANTAGONIST OF CASR

Also Published As

Publication number Publication date
MY138734A (en) 2009-07-31
US20080255042A1 (en) 2008-10-16
IL169575A0 (en) 2007-07-04
RU2315036C2 (ru) 2008-01-20
EP2189439A3 (en) 2011-05-04
EP1619180A1 (en) 2006-01-25
KR20050094047A (ko) 2005-09-26
RU2005123985A (ru) 2006-01-27
EP2308828A3 (en) 2013-05-22
NO20054868L (no) 2005-12-20
AU2004232604B8 (en) 2004-11-04
CA2513738A1 (en) 2004-11-04
EP1619180A4 (en) 2006-05-24
DE602004024668D1 (de) 2010-01-28
MXPA05007609A (es) 2005-09-30
AU2004232604A1 (en) 2004-11-04
AU2004232604C1 (en) 2008-06-05
TW200505823A (en) 2005-02-16
EP1619180B1 (en) 2009-12-16
ATE452121T1 (de) 2010-01-15
CN1741984A (zh) 2006-03-01
BRPI0407097A (pt) 2006-01-24
JP3751312B2 (ja) 2006-03-01
CN101723921A (zh) 2010-06-09
PT1619180E (pt) 2009-12-29
HK1083096A1 (en) 2006-06-23
AU2004232604B2 (en) 2007-09-13
JPWO2004094362A1 (ja) 2006-07-13
US20090326058A1 (en) 2009-12-31
CY1109880T1 (el) 2014-09-10
US20120301552A1 (en) 2012-11-29
NZ541188A (en) 2008-01-31
AR044075A1 (es) 2005-08-24
SI1619180T1 (sl) 2010-04-30
ZA200505587B (en) 2006-09-27
DK1619180T3 (da) 2010-03-29
KR100696927B1 (ko) 2007-03-20
WO2004094362A1 (ja) 2004-11-04
ES2337576T3 (es) 2010-04-27
NO20054868D0 (no) 2005-10-21
CN100577633C (zh) 2010-01-06
EP2308828A2 (en) 2011-04-13
AU2004232604A8 (en) 2004-11-04
EP2189439A2 (en) 2010-05-26
US7304174B2 (en) 2007-12-04
US20050032796A1 (en) 2005-02-10
PE20050460A1 (es) 2005-07-08
HRP20100042T1 (hr) 2010-02-28
TWI329628B (en) 2010-09-01
CL2004000868A1 (es) 2005-01-21
IL169575A (en) 2011-07-31
CA2513738C (en) 2010-04-06
PL1619180T3 (pl) 2010-05-31

Similar Documents

Publication Publication Date Title
CO5640091A2 (es) Antagonista de un receptor sensible al calcio
PE20030808A1 (es) Derivados triciclicos heterociclicos como antagonistas receptores de trombina
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
EA200971100A1 (ru) Производные фталазинона в качестве ингибиторов поли(адф-рибоза)полимеразы (parp-1)
CO5601018A2 (es) Derivados de n-fenil-2-pirimidin-amina
PE20061335A1 (es) Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c
CO5550398A2 (es) 7-aminotriazolpirimidinas, proceso e intermedios para su preparacion, composiciones que las comprenden y su uso para controlar hongos dañinos
BRPI0606455A (pt) compostos farmacêuticos
PE20030762A1 (es) Compuestos heterociclicos como antagonistas nk1
CO5261616A1 (es) Inhibidores no peptidicos de la union celular dependientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
RS53061B (en) INHIBITORI PROTEIN KINAZE
CO5611147A2 (es) Derivados de nicotinamida utiles como inhibidores p38
PE20061164A1 (es) Piperazin-piperidinas sustituidas con pirazinilo con actividad antagonista de cxcr3
AR054130A1 (es) Procedimiento para la preparacion de 1-alquil-3-feniluracilos
CO6241101A2 (es) Derivados de quinolina como inhibidores de la p13 quinasa
CO5690582A2 (es) Derivados de n-tiazol-2-il-benzamida
CO6190521A2 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta -9 desaturasa
PE20130647A1 (es) Indoles
CO5540344A2 (es) Medicamentos
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
CO5611110A2 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion, composiciones farmaceuticas y usos de los mismos
AR038341A1 (es) Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l
PE20060483A1 (es) Compuestos heterociclicos como antagonistas de nk1
TW200745058A (en) MMP-13 selective inhibitors
AR035759A1 (es) Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos

Legal Events

Date Code Title Description
FC Application refused
FG Application granted